Study of Pexidartinib with Radiation and Temozolomide for Glioblastoma
Author Information
Author(s): Joe S. Mendez, Adam L. Cohen, Midori Eckenstein, Randy L. Jensen, Lindsay M. Burt, Karen L. Salzman, Marc Chamberlain, Henry H. Hsu, Marguerite Hutchinson, Fabio Iwamoto, Keith L. Ligon, Maciej M. Mrugala, Michael Pelayo, Scott R. Plotkin, Vinay K. Puduvalli, Jeffrey Raizer, David A. Reardon, Michael Sterba, Tobias Walbert, Brian L. West, Eric T. Wong, Chao Zhang, Howard Colman
Primary Institution: Huntsman Cancer Institute, Salt Lake City, UT, USA
Hypothesis
Can pexidartinib improve treatment outcomes in patients with newly diagnosed glioblastoma when combined with radiation therapy and temozolomide?
Conclusion
Pexidartinib combined with standard treatment did not improve survival outcomes in glioblastoma patients but was generally safe and well tolerated.
Supporting Evidence
- The recommended Phase 2 dose of pexidartinib was established at 800 mg/day.
- Median progression-free survival was 6.7 months.
- Median overall survival was 13.1 months.
- Pexidartinib was generally safe and well tolerated.
- Pharmacodynamic studies showed modulation of systemic markers.
- Patient demographics included a median age of 56 years.
- Thirty patients had methylated MGMT status.
- Sixty-five patients were enrolled across multiple institutions.
Takeaway
This study tested a new drug with standard treatments for brain cancer, but it didn't help patients live longer, even though it was safe to use.
Methodology
This was a multicenter, open-label, dose-escalation trial assessing the safety and efficacy of pexidartinib combined with radiation therapy and temozolomide.
Potential Biases
The use of historical controls may introduce bias due to differences in patient populations and treatment protocols.
Limitations
The study design was a single-arm trial, which may limit the ability to draw definitive conclusions about efficacy compared to historical controls.
Participant Demographics
{"median_age":56,"sex_distribution":{"male":41,"female":24},"race":{"white":58,"other":7},"MGMT_status":{"methylated":30,"unmethylated":30}}
Statistical Information
P-Value
{"mPFS":0.456,"mOS":0.389}
Confidence Interval
{"mPFS":"90% CI: 4.5, 11.5","mOS":"90% CI: 11.5, 24.5"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website